One Two
Sie sind hier: Startseite Abteilungen Allgemeine Psychologie I Mitarbeiterinnen und Mitarbeiter Ulrich Ettinger

Ulrich Ettinger

UE

 

Prof. Dr. Ulrich Ettinger

Leiter der Abteilung für Allgemeine Psychologie I

Institut für Psychologie
Allgemeine Psychologie I
Kaiser-Karl-Ring 9
D-53111 Bonn

Raum 3.016

Tel.: 0228/73-4208
Fax: 0228/73-62323
Skype: ulrich.ettinger
Email: ulrich.ettinger at uni-bonn.de

 

Sprechstunde: Dienstag 9:00-10:00 Uhr und nach Vereinbarung

 


BAföG-Beauftragter der Philosophischen Fakultät zur Erteilung von Leistungsbescheinigungen für die Buchstaben A-C

Für Leistungsbescheinigungen können Sie sich in meiner Sprechstunde an mich wenden oder per Email einen Termin mit mir vereinbaren.

Bitte beachten Sie folgenden Hinweis: Um eine Bestätigung zur Verlängerung der Förderung durch BAföG zu erhalten, bringen Sie bitte Ihr Transcript of Records, Ihren Studierendenausweis sowie das Formblatt der BAföG-Stelle mit.

 

 

Forschungsinteressen

  • Kognitive Psychopharmakologie

  • Okulomotorik

  • Schizophrenie und Schizotypie

  • Inhibition und Impulsivität

  • Verhaltens- und Molekulargenetik der Kognition sowie Gehirnfunktion und -struktur

 

 

Studium und Werdegang

seit 04/2012: Professor für Psychologie, Institut für Psychologie, Rheinische Friedrich-Wilhelms-Universität, Bonn

01/2009 – 03/2012: Leiter einer DFG Emmy Noether Gruppe, Klinik für Psychiatrie und Psychotherapie sowie Department Psychologie (Allgemeine und Experimentelle Psychologie), Ludwig-Maximilians-Universität, München

10/2004 – 12/2008: Research Fellow und Lecturer / Senior Lecturer, Centre for Neuroimaging Sciences, Institute of Psychiatry, King’s College London, UK

10/2003 – 09/2004: Richard H. Tomlinson Postdoctoral Research Fellow, Department of Psychology und Douglas Hospital, McGill University, Montreal, Canada

10/2002 – 09/2003: Postdoctoral Research Worker, Division of Psychological Medicine, Institute of Psychiatry, King’s College London, UK

09/1999 – 09/2002: Promotion, Department of Psychology, Goldsmiths College, und Division of Psychological Medicine, Institute of Psychiatry, King's College London, UK

09/1995 - 09/1999: Studium der Psychologie und Neurowissenschaft, Goldsmiths College und King's College London, UK

 

 

Drittmittel

Für die finanzielle Unterstützung meiner Forschung (in Höhe von insgesamt ca. €2.100.000) danke ich:

  • DFG
  • ESRC (UK)
  • MRC (UK)
  • NIHR (UK)
  • VolkswagenStiftung
  • Friedrich-Baur-Stiftung
  • FöFoLe (LMU)
  • British Academy (UK)
  • Leverhulme Trust (UK)

 

 

Preise und Auszeichnungen

  • Psychopharmacology Award, British Association for Psychopharmacology (06/2014)
  • Lehrpreis der Universität Bonn (06/2013)
  • Rafaelsen Award, Collegium Internationale Neuro-Psychopharmacologicum (03/2009)
  • Young Scientist Award, 14th Biennial Winter Workshop on Schizophrenia (11/2007)
  • Förderpreis, Deutsche Gesellschaft für Biologische Psychiatrie (08/2006)
  • Young Investigator Award, International Congress on Schizophrenia Research (02/2005)
  • Travel Award, Organisation for Human Brain Mapping (05/2004)
  • Young Scientist Award, 12th Biennial Winter Workshop on Schizophrenia (11/2003)
  • Young Scientist Award, 11th Biennial Winter Workshop on Schizophrenia (11/2001)
  • Bursary, Department of Psychology (Goldsmiths College), Promotionsstipendium (09/1999)
  • Studentship, Section of Cognitive Psychopharmacology (Institute of Psychiatry), Promotionsstipendium (09/1999)
  • Bursary, Department of Neuroscience (Institute of Psychiatry) (10/1998)
  • Goldsmiths Psychology Prize (09/1998)

 

 

Herausgebertätigkeiten

Seit 10/2015: Editorial Board, Journal of Eye Movement Research

Seit 06/2015: Editorial Board, Journal of Affective Disorders

Seit 01/2014: Action Editor, Brain and Cognition

Seit 04/2013: Associate Editor, Frontiers in Psychiatry

 

 

Publikationen

 

Originalarbeiten in Zeitschriften mit Peer Review

  • Meyhöfer I, Kumari V, Hill A, Petrovsky N, Ettinger U (in press). Sleep deprivation as an experimental model system for psychosis: Effects on smooth pursuit, prosaccades, and antisaccades. Journal of Psychopharmacology.
  • Oberlader VA, Ettinger U, Banse R, Schmidt AF (in press). Development of a Cued Pro- and Antisaccade Paradigm: An Indirect Measure to Explore Automatic Components of Sexual Interest. Archives of Sexual Behavior.
  • Kasparbauer AM, Meyhöfer I, Steffens M, Weber B, Aydin M, Kumari V, Hurlemann R, Ettinger U (in press). Neural effects of methylphenidate and nicotine during smooth pursuit eye movements. NeuroImage.
  • Steffens M, Becker B, Neumann C, Kasparbauer AM, Meyhöfer I, Weber B, Mehta MA, Hurlemann R, Ettinger U (in press). Effects of Ketamine on Brain Function during Smooth Pursuit Eye Movements. Human Brain Mapping.
  • Talanow T, Kasparbauer AM, Steffens M, Meyhöfer I, Weber B, Smyrnis N, Ettinger U (in press). Facing Competition: Neural Mechanisms Underlying Parallel Programming of Antisaccades and Prosaccades. Brain & Cognition.
  • Gunnarsson B, Jónsdóttir GA, Björnsdóttir G, Konte B, Sulem P, Kristmundsdóttir S, Kehr B, Gústafsson O, Helgason H, Iordache PD, Ólafsson S, Frigge ML, Þorleifsson G, Arnarsdóttir S, Stefánsdóttir B, Giegling I, Djurovic S, Sundet KS, Espeseth T, Melle I, Hartmann AM, Thorsteinsdottir U, Kong A, Guðbjartsson DF, Ettinger U, Andreassen OA, Rujescu D, Halldórsson J, Stefánsson H, Halldórsson BV, Stefánsson K (in press). A sequence variant associating with educational attainment also affects childhood cognition. Scientific Reports.
  • Antonova E, Amaratunga K, Wright B, Ettinger U, Kumari V (in press). Schizotypy and Mindfulness: Magical Thinking without Suspiciousness Characterises Mindfulness Meditators. Schizophrenia Research: Cognition.
  • Wright B, Peters E, Ettinger U, Kuipers E, Kumari V (in press). Moderators of Noise-induced Cognitive Change in Healthy Adults. Noise and Health.
  • Kambeitz J, la Fougère C, Werner N, Pogarell O, Riedel M, Falkai P, Ettinger U (in press). Nicotine-Dopamine-Transporter Interactions During Reward-Based Decision Making. European Neuropsychopharmacology.
  • Wright B, Peters E, Ettinger U, Kuipers E, Kumari V (in press). Effects of Environmental Noise on Cognitive (Dys)functions in Schizophrenia: A Pilot Within-Subjects Experimental Study. Schizophrenia Research.
  • Koychev I, Joyce D, Barkus E, Ettinger U, Schmechtig A, Dourish CT, Dawson GR, Craig KJ, Deakin JFW (in press). Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies. Translational Psychiatry.
  • Meyhöfer I, Bertsch K, Esser M, Ettinger U (in press). Variance in Saccadic Eye Movements Reflects Stable Traits. Psychophysiology.
  • Picchioni M, Toulopoulou T, Chaddock C, Cole J, Ettinger U, Oses A, Metcalfe H, Lombardi A, Lico C, Murray RM, McGuire P (in press). Familial and Unique Environmental Influences on Brain Volumes in Twins with Schizophrenia. Journal of Psychiatry and Neuroscience.
  • Ettinger U, Merten N, Kambeitz J (2016) Meta-analysis of the Association of the SLC6A3 3’-UTR VNTR with Cognition. Neuroscience & Biobehavioral Reviews, 60, 72-81.
  • Polner B, Aichert D, Macare C, Costa A, Ettinger U (2015). Gently Restless: Association of ADHD-like Traits with Response Inhibition and Interference Control. European Archives of Psychiatry and Clinical Neuroscience, 265(8), 689-699.
  • Kumari V, Ettinger U, Lee S, Deuschl C, Anilkumar A, Schmechtig A, Corr P, ffytche D, Williams S (2015). Common and Distinct Neural Effects of Risperidone and Olanzapine during Procedural Learning in Schizophrenia: A Randomised Longitudinal fMRI Study. Psychopharmacology, 232(17), 3135-3134.
  • Schulze-Rauschenbach S, Lennertz L, Ruhrmann S, Petrovsky N, Ettinger U, Pukrop R, Dreher J, Klosterkötter J, Maier W, Wagner M (2015). Neurocognitive functioning in parents of schizophrenia patients: Attentional and executive performance vary with genetic loading. Psychiatry Research, 230(3), 885-891.
  • Kasparbauer AM, Merten N, Aichert DS, Wöstmann N, Meindl T, Rujescu D, Ettinger U (2015). Association of COMT and SLC6A3 Polymorphisms with Impulsivity, Response Inhibition and Brain Function. Cortex, 71, 219-231.
  • Meyhöfer I, Steffens M, Kasparbauer A, Grant P, Weber B, Ettinger U (2015). Neural Mechanisms of Smooth Pursuit Eye Movements in Schizotypy. Human Brain Mapping, 36(1), 340-353.
  • Kasparbauer AM, Rujescu D, Riedel M, Pogarell O, Costa A, Meindl T, la Fougère C, Ettinger U (2015). Methylphenidate Effects on Brain Activity as a Function of SLC6A3 Genotype and Striatal Dopamine Transporter Availability. Neuropsychopharmacology, 40(3), 736-745.
  • Herweg N, Weber B, Kasparbauer A, Meyhöfer I, Steffens M, Smyrnis N, Ettinger U (2014). Functional Magnetic Resonance Imaging of Sensorimotor Transformations in Saccades and Antisaccades. NeuroImage, 102(Pt 2), 848-860.
  • Mueller S, Costa A, Keeser D, Pogarell O, Berman A, Coates U, Reiser MF, Riedel M, Möller HJ, Ettinger U, Meindl T (2014) The Effects of Methylphenidate on Whole Brain Intrinsic Functional Connectivity. Human Brain Mapping, 35(11), 5379-5388.
  • Petrovsky N*, Ettinger U*, Hill A, Frenzel L, Meyhöfer I, Wagner M, Backhaus J, Kumari V (2014). Sleep deprivation disrupts prepulse inhibition and induces psychosis-like symptoms in healthy humans. Journal of Neuroscience, 34(27), 9134-9140. * shared first authorship
  • Macare C, Meindl T, Nenadic I, Rujescu D, Ettinger U (2014). Preliminary Findings on the Heritability of the Neural Correlates of Response Inhibition. Biological Psychology, 103, 19-23.
  • Hamm JP, Crawford TJ, Nebl H, Kean M, Williams SCR, Ettinger U (2014). Neural correlates of illusory line motion. PLoS ONE, 9(1):e87595. doi: 10.1371/journal.pone.0087595.
  • Kambeitz J, Romanos M, Ettinger U (2014). Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. The Pharmacogenomics Journal, 14(1), 77-84.
  • Saville CWN, Lancaster TM, Stefanou ME, Salunkhe G, Lourmpa I, Nadkarni A, Boehm SG, Bender S, Smyrnis N, Ettinger U, Feige B, Biscaldi M, Mantripragada KK, Linden DEJ, Klein C (2014) COMT Val158Met genotype is associated with fluctuations in working memory performance: converging evidence from behavioural and single-trial P3b measures. NeuroImage, 100, 489-497.
  • Cutsuridis V, Kumari V, Ettinger U (2014). Antisaccade Performance in Schizophrenia: A Neural Model of Decision Making in the Superior Colliculus. Frontiers in Decision Neuroscience, 8:13, doi: 10.3389/fnins.2014.00013.
  • Petrovsky N, Ettinger U, Quednow BB, Landsberg MW, Drees J, Lennertz L, Frommann I, Heilmann K, Sträter B, Kessler H, Dahmen N, Mössner R, Maier W, Wagner M (2013). Nicotine enhances antisaccade performance in schizophrenia patients and healthy controls. International Journal of Neuropsychopharmacology, 16(7), 1473-1481.
  • Petrovsky N, Ettinger U, Kessler H, Mössner R, Wolfsgruber S, Dahmen N, Maier W, Wagner M, Quednow BB (2013). The effect of nicotine on sensorimotor gating is modulated by a CHRNA3 polymorphism. Psychopharmacology, 229(1), 31-40.
  • Perkins AM, Cserjesi R, Ettinger U, Kumari V, Martin NG, Arden R (2013). Personality and occupational markers of 'solid citizenship' are associated with having fewer children. Personality and Individual Differences, 55(8), 871-876.
  • Perkins AM, Leonard A, Krueger K, Dalton J, Mehta MA, Kumari V, Williams SCR, Ettinger U (2013). A dose of ruthlessness: interpersonal moral judgment is hardened by the anti-anxiety drug lorazepam. Journal of Experimental Psychology: General. 142(3), 612-20.
  • Perkins AM, Ettinger U, Weaver K, Schmechtig A, Schrantee A, Morrison PD, Sapara A, Kumari V, Williams SCR, Corr PK (2013). Advancing the defensive explanation for anxiety disorders: lorazepam effects on human defense are systematically modulated by personality and threat-type. Translational Psychiatry, 3, e246. doi: 10.1038/tp.2013.20.
  • Wöstmann NM, Aichert DS, Costa A, Rubia K, Möller HJ, Ettinger U (2013). Reliability and plasticity of response inhibition and interference control. Brain and Cognition, 81(1), 82-94.
  • Aichert DS, Derntl B, Wöstmann NM, Groß JK, Dehning S, Cerovecki A, Möller HJ, Habel U, Riedel M, Ettinger U (2013). Intact emotion-cognition interaction in schizophrenia patients and first-degree relatives: Evidence from an emotional antisaccade task. Brain and Cognition, 82(3), 329-336.
  • Schmechtig A, Lees J, Perkins A, Altavilla A, Craig KJ, Dawson GR, Deakin JFW, Dourish CT, Evans LH, Koychev I, Weaver K, Smallman R, Walters J, Wilkinson LS, Morris R, Williams SCR, Ettinger U (2013). The Effects of Ketamine and Risperidone on Eye Movement Control in Healthy Volunteers. Translational Psychiatry. 3:e334. doi: 10.1038/tp.2013.109
  • Ettinger U, Corr PJ, Mofidi A, Williams SCR, Kumari V (2013). Dopaminergic basis of the psychosis-prone personality investigated with functional magnetic resonance imaging of procedural learning. Frontiers in Human Neuroscience, Vol 7, Article 130.
  • Schmechtig A, Lees J, Grayson L, Craig KJ, Dadhiwala R, Dawson GR, Deakin JFW, Dourish CT, Koychev I, McMullen K, Migo EM, Perry C, Wilkinson L, Morris R, Williams SCR, Ettinger U (2013). Effects of Risperidone, Amisulpride and Nicotine on Eye Movement Control and their Modulation by Schizotypy. Psychopharmacology, 227, 331-345.
  • Antoniades C, Ettinger U, Gaymard B, Gilchrist I, Kristjansson A, Kennard C, Leigh J, Noorani I, Pouget P, Smyrnis N, Tarnowski A, Zee D, Carpenter RHS (2013). An internationally standardised antisaccade protocol for clinical use. Vision Research, 84, 1-5.
  • Segal NL, Graham J, Ettinger U (2013). Unrelated Look-Alikes: A Replicated Study of Personality Similarity and New Qualitative Findings on Social Relatedness. Personality and Individual Differences, 55, 169-174.
  • Costa A, Riedel M, Pogarell O, Menzel-Zelnitschek F, Schwarz M, Reiser M, Möller HJ, Rubia K, Meindl T, Ettinger U (2013). Methylphenidate effects on neural activity during response inhibition in healthy humans. Cerebral Cortex, 23, 1179-1189.
  • Costa A, la Fougere C, Pogarell O, Möller HJ, Riedel M, Ettinger U (2013). Impulsivity is related to striatal dopamine transporter availability in healthy males. Psychiatry Research: Neuroimaging, 211, 251-256.
  • Liepelt R, Schneider J, Aichert DS, Wöstmann N, Dehning S, Möller HJ, Riedel M, Dolk T, Ettinger U (2012). Action Blind: Disturbed Self-other Integration in Schizophrenia. Neuropsychologia, 50(14), 3775-3780.
  • Macare C, Bates TC, Heath AC, Martin NG, Ettinger U (2012). Substantial genetic overlap between schizotypy and neuroticism: A twin study. Behavior Genetics, 42(5), 732-742.
  • Aichert DS, Wöstmann NM, Costa A, Macare C, Wenig JR, Möller HJ, Rubia K, Ettinger U (2012). Associations between Trait Impulsivity and Prepotent Response Inhibition. Journal of Experimental and Clinical Neuropsychology, 34(10), 1016-1032.
  • Allman AA, Ettinger U, Joober R, O'Driscoll GA (2012). Effects of methylphenidate on basic and higher-order oculomotor functions. Journal of Psychopharmacology, 26(11), 1471-1479.
  • Völter C, Strobach T, Aichert DS, Wöstmann N, Costa A, Möller HJ, Schubert T, Ettinger U (2012). Schizotypy and behavioural adjustment and the role of neuroticism. PLoS ONE, 7(2), e30078.
  • Völter C, Riedel M, Wöstmann N, Aichert D, Lobo S, Costa A, Schmechtig A, Collier DA, Hartmann AM, Giegling I, Möller HJ, Quednow BB, Rujescu D, Kumari V, Ettinger U (2012). Sensorimotor gating and D2 receptor signalling: evidence from a molecular genetic approach. International Journal of Neuropsychopharmacology, 15(10), 1427-1440.
  • Aichert DS, Williams SCR, Möller HJ, Kumari V, Ettinger U (2012). Functional neural correlates of psychometric schizotypy: an fMRI study of antisaccades. Psychophysiology, 49(3), 345-356.
  • Ettinger U, Williams SCR, Meisenzahl EM, Möller HJ, Kumari V, Koutsouleris N (2012). Association between brain structure and psychometric schizotypy in healthy individuals. World Journal of Biological Psychiatry, 13(7), 544-549.
  • Petrovsky N, Ettinger U, Quednow BB, Walter H, Schnell K, Kessler H, Mössner R, Maier W, Wagner M (2012). Nicotine differentially modulates antisaccade performance in healthy male non-smoking volunteers stratified for low and high accuracy. Psychopharmacology, 221(1), 27-38.
  • Premkumar P, Ettinger U, Inchley-Mort S, Sumich A, Williams SCR, Kuipers E, Kumari V (2012). Neural processing of social rejection: the role of schizotypal personality traits. Human Brain Mapping, 33(3), 695-706.
  • Owens SF, Picchioni M, Ettinger U, McDonald C, Walshe M, Schmechtig A, Murray R, Rijsdijk F, Toulopoulou T (2012). Prefrontal deviations in function but not volume are putative endophenotypes for schizophrenia. Brain, 135(Pt 7), 2231-2244.
  • Koychev I, McMullen K, Lees J, Dadhiwala R, Perry C, Schmechtig A, Walters J, Craig KJ, Dawson GR, Dourish CT, Ettinger U, Wilkinson L, Williams S, Deakin JFW, Barkus E (2012). A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-centre double-blind placebo-controlled study. European Neuropsychopharmacology, 22(7), 469-481.
  • Ettinger U, Schmechtig A, Toulopoulou T, Borg C, Orrells C, Owens S, Matsumoto K, van Haren NE, Hall MH, Kumari V, McGuire PK, Murray RM, Picchioni M (2012). Prefrontal and striatal volumes in monozygotic twins concordant and discordant for schizophrenia. Schizophrenia Bulletin, 38(1), 192-203.
  • Ettinger U, Williams SCR, Fannon D, Premkumar P, Kuipers E, Möller HJ, Kumari V (2011). Functional magnetic resonance imaging of a parametric working memory task in schizophrenia: relationship with performance and effects of antipsychotic treatment. Psychopharmacology, 216(1), 17-27.
  • Costa A, Riedel M, Müller U, Möller HJ, Ettinger U (2011). Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human SPECT studies. Synapse, 65(10), 998-1005.
  • Quednow BB, Ettinger U, Mössner R, Rujescu D, Giegling I, Collier DA, Schmechtig A, Kühn KU, Möller HJ, Maier W, Wagner M, Kumari V (2011). The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers. Journal of Neuroscience, 31(18), 6684-6691.
  • Kempton MJ, Underwood TS, Brunton S, Stylios F, Schmechtig A, Ettinger U, Smith MS, Lovestone S, Crum WR, Frangou S, Williams SC, Simmons A (2011). A comprehensive testing protocol for neuroanatomical segmentation techniques: Evaluation of a novel lateral ventricle segmentation method. NeuroImage, 58(4), 1051-1059.
  • Perkins AM, Ettinger U, Williams SCR, Reuter M, Hennig J, Corr PJ (2011). Flight behaviour in humans is intensified by a candidate genetic risk factor for panic disorder: evidence from a translational model of fear and anxiety. Molecular Psychiatry, 16(3), 242-244.
  • Kempton M*, Ettinger U*, Foster R, Williams SCR, Calvert G, Hampshire A, Zelaya F, O’Gorman R, McMorris T, Owen AM, Smith M (2011). Dehydration affects brain structure and function in healthy adolescents. Human Brain Mapping, 32(1), 71-79. * shared first authorship
  • Hall MH, Taylor G, Sham P, Schulze K, Rijsdijk F, Picchioni M, Toulopoulou T, Ettinger U, Bramon E, Murray RM, Salisbury DF (2011). The early auditory gamma band response is heritable and a putative endophenotype of schizophrenia. Schizophrenia Bulletin, 37(4), 778-787.
  • Schmechtig A, Vassos E, Kumari V, Hutton SB, Collier DA, Morris RG, Williams SCR, Ettinger U (2010). Association of Neuregulin 1 rs3924999 genotype with antisaccades and smooth pursuit eye movements. Genes, Brain and Behavior, 9(6), 621-627.
  • Borgwardt SJ, Picchioni M, Ettinger U, Toulopoulou T, Murray R, McGuire PK (2010). Gray matter volume in monozygotic twins with schizophrenia – a voxel-based morphometry study. Biological Psychiatry, 67(10), 956-964.
  • Petrovsky N, Quednow BB, Ettinger U, Schmechtig A, Mössner R, Collier D, Kühn KU, Maier W, Wagner M, Kumari V (2010). Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacology, 35(7), 1429-1439.
  • Crawford TJ, Hamm JP, Kean M, Schmechtig A, Kumari V, Anilkumar AP, Ettinger U (2010). The perception of real and illusory motion in schizophrenia. Neuropsychologia, 48(10), 3121-3127.
  • Haraldsson HM, Ettinger U, Magnusdottir BB, Ingason A, Hutton SB, Sigmundsson T, Sigurdsson E, Petursson H (2010). Neuregulin-1 genotypes and eye movements in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 260(1), 77-85.
  • Haraldsson HM, Ettinger U, Magnusdottir BB, Sigmundsson T, Sigurdsson E, Ingason A, Petursson H (2010). Catechol-O-methyltransferase Val 158 Met polymorphism and antisaccade eye movements in schizophrenia. Schizophrenia Bulletin, 36(1), 157-164.
  • Perkins AM, Ettinger U, Davis R, Foster R, Williams SCR, Corr PJ (2009). Effects of lorazepam and citalopram on human defensive reactions: ethopharmacological differentiation of fear and anxiety. Journal of Neuroscience, 29(40), 12617-12624.
  • Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Réthelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA; Genetic Risk and Outcome in Psychosis (GROUP), Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA (2009). Common variants conferring risk of schizophrenia. Nature, 460(7256), 744-747.
  • Quednow BB, Schmechtig A, Ettinger U, Petrovsky N, Collier DA, Vollenweider FX, Wagner M, Kumari V (2009). Sensorimotor gating depends on polymorphisms of the 5-HT2A receptor and COMT, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biological Psychiatry, 66(6), 614-620.
  • Ettinger U, Williams SCR, Patel D, Michel TM, Nwaigwe M, Caceres A, Mehta M, Anilkumar AP, Kumari V (2009). Effects of acute nicotine on brain function in healthy smokers and non-smokers: estimation of inter-individual response heterogeneity. NeuroImage, 45, 549-561.
  • Petrovsky N, Schmechtig A, Flomen RH, Kumari V, Collier D, Makoff A, Wagner M, Ettinger U (2009). CHRFAM7A copy number and 2bp deletion polymorphisms and antisaccade performance. International Journal of Neuropsychopharmacology, 12, 267-273.
  • Haraldsson HM, Ettinger U, Magnusdottir BB, Sigmundsson T, Sigurdsson E, Ingason A, Petursson H (2009). COMT val158met genotype and smooth pursuit eye movements in schizophrenia. Psychiatry Research, 169, 173-175.
  • Hardoon D, Ettinger U, Mourao-Miranda J, Antonova E, Collier D, Kumari V, Williams SCR, Brammer M (2009). Correlation based multivariate analysis of genetic influence on brain volume. Neuroscience Letters, 450, 281-286.
  • Petrovsky N, Weiss-Motz F, Schulze-Rauschenbach S, Lemke M, Hornung P, Ruhrmann S, Klosterkötter J, Maier W, Ettinger U, Wagner M (2009). Antisaccade performance is related to genetic loading for schizophrenia. Journal of Psychiatric Research, 43, 291-297.
  • Kempton MJ, Ettinger U, Schmechtig A, Winter EM, Smith L, McMorris T, Wilkinson I, Williams SCR, Smith M (2009). Effects of acute dehydration on brain morphology in healthy humans. Human Brain Mapping, 30, 291-298.
  • Rujescu D, Ingason A, Cichon S, Pietiläinen OPH, Barnes M, Toulopoulou T, Picchioni M, Vassos E, Ettinger U, Bramon E, Murray R, Ruggeri M, Tosato S, Bonetto C, Steinberg S, Sigurdsson E, Sigmundsson T, Petursson H, Gylfason A, Olason PI, Hardarsson G, Jonsdottir GA, Gustafsson O, Fossdal R, Giegling I, Möller HJ, Hartmann A, Hoffmann P, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Andreassen OA, Djurovic S, Hansen T, Werge T, Melle I, Kiemeney LA, Franke B, Buizer-Voskamp JE, Ophoff R, GROUP Investigators, Rietschel M, Noethen M, Stefansson K, Peltonen L, St Clair D, Stefansson H, Collier D (2009). Disruption of the neurexin 1 gene is associated with schizophrenia. Human Molecular Genetics, 18, 988-996.
  • Ettinger U, Kumari V, Collier DA, Powell J, Luzi S, Michel TM, Zedomi O, Williams SCR (2008). Catechol-O-methyltransferase (COMT) val158met genotype is associated with brain activation as a function of task characteristic. Neuropsychopharmacology, 33, 3046-3057.
  • Haraldsson HM, Ettinger U, Magnusdottir BB, Sigmundsson T, Sigurdsson E, Petursson H (2008). Eye movement deficits in schizophrenia: investigation of a genetically homogenous Icelandic sample. European Archives of Psychiatry and Clinical Neuroscience, 258, 373-383.
  • Kempton MJ, Geddes JR, Ettinger U, Williams SCR, Grasby PM (2008). Meta-analysis, database and meta-regression of 98 structural imaging studies in bipolar disorder. Archives of General Psychiatry, 65, 1017-1032.
  • Sumich A, Kumari V, Dodd P, Ettinger U, Hughes C, Zachariah E, Sharma T (2008). N100 and P300 amplitude to Go and No-Go variants of the auditory oddball in siblings discordant for schizophrenia. Schizophrenia Research, 98, 265-277.
  • Ettinger U, ffytche DH, Kumari V, Kathmann N, Reuter B, Zelaya F, Williams SCR (2008). Decomposing the neural correlates of antisaccade eye movements using event-related fMRI. Cerebral Cortex, 18, 1148-1159.
  • Ettinger U, Picchioni M, Landau S, Matsumoto K, Van Haren N, Marshall N, Hall MH, Schulze K, Toulopoulou T, Davies N, Ribchester T, McGuire PK, Murray RM (2007). Magnetic resonance imaging of the thalamus and adhesio interthalamica in twins with schizophrenia. Archives of General Psychiatry, 64, 401-409.
  • Toulopoulou T, Picchioni M, Rijsdijk F, Hall MH, Ettinger U, Sham P, Murray R (2007). Substantial genetic overlap between neurocognition and schizophrenia: genetic modelling in twin samples. Archives of General Psychiatry. 64, 1348-1355.
  • Hall MH, Rijsdijk F, Picchioni M, Schulze K, Ettinger U, Toulopoulou T, Bramon E, Murray RM, Sham P (2007). Substantial shared genetic influences on schizophrenia and event-related potentials. American Journal of Psychiatry. 164, 804-812.
  • Ettinger U, Picchioni M, Hall MH, Schulze K, Toulopoulou T, Landau S, Crawford TJ, Murray RM (2006). Antisaccade performance in monozygotic twins discordant for schizophrenia: The Maudsley twin study. American Journal of Psychiatry, 163, 543-545.
  • Ettinger U, Joober R, De Guzman R, O’Driscoll GA (2006). Schizotypy, attention deficit hyperactivity disorder features, and dopamine genes. Psychiatry and Clinical Neurosciences, 60, 764-767.
  • Hall MH, Schulze K, Rijsdijk F, Picchioni M, Ettinger U, Bramon E, Freedman R, Murray RM, Sham P (2006). Heritability and reliability of P300, P50 and duration mismatch negativity. Behavior Genetics, 36(6), 845-857.
  • Ettinger U, Hejda S, Flak V, Corr PJ (2005). Prepulse inhibition of the acoustic startle reflex and oculomotor control. Psychophysiology, 42(4), 473-482.
  • Ettinger U, Antonova E, Crawford TJ, Mitterschiffthaler MT, Goswani S, Sharma T, Kumari V (2005). Structural neural correlates of antisaccade and prosaccade eye movements in healthy humans. NeuroImage, 24, 487-494.
  • Ettinger U, Kumari V, Crawford TJ, Flak V, Sharma T, Davis RE, Corr PJ (2005). Saccadic eye movements, schizotypy, and the role of neuroticism. Biological Psychology, 68(1), 61-78.
  • Kumari V, Das M, Zachariah E, Ettinger U, Sharma T (2005). Reduced prepulse inhibition in unaffected siblings of schizophrenia patients. Psychophysiology 42, 588-594.
  • Kumari V, Antonova E, Zachariah E, Galea A, Aasen I, Ettinger U, Mitterschiffthaler MT, Sharma T (2005). Structural brain correlates of prepulse inhibition of the acoustic startle response in healthy humans. NeuroImage 26, 1052-1058.
  • Hughes C, Kumari V, Das M, Zachariah E, Ettinger U, Sumich A, Sharma T (2005). Cognitive functioning in siblings discordant for schizophrenia. Acta Psychiatrica Scandinavica, 111(3), 185-192.
  • Kumari V, Ettinger U, Crawford TJ, Zachariah E, Sharma T (2005). Lack of association between prepulse inhibition and antisaccadic deficits in chronic schizophrenia: Implications for identification of schizophrenia endophenotypes. Journal of Psychiatric Research, 39, 227-240.
  • Ettinger U, Kumari V, Chitnis XA, Corr PJ, Crawford TJ, Fannon DG, O’Ceallaigh S, Sumich AL, Doku V, Sharma T (2004). Volumetric neural correlates of antisaccade eye movements in first-episode psychosis. American Journal of Psychiatry, 161, 1918-1921.
  • Ettinger U, Kumari V, Crawford TJ, Corr PJ, Das M, Hughes C, Sumich AL, Zachariah E, Rabe-Hesketh S, Sharma T (2004). Smooth pursuit and antisaccade eye movements in siblings discordant for schizophrenia. Journal of Psychiatric Research, 38, 177-184.
  • Das M, Kumari V, Soni W, Ettinger U, Binneman B, Hughes C, Mehrotra R, Sharma T (2004). Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia. Schizophrenia Bulletin, 30(2), 241-253.
  • Ettinger U, Kumari V, Zachariah E, Galea A, Crawford TJ, Corr PJ, Taylor D, Das M, Sharma T (2003). Effects of procyclidine on eye movements in schizophrenia. Neuropsychopharmacology, 28, 2199-2208.
  • Ettinger U, Kumari V, Crawford TJ, Davis RE, Sharma T, Corr PJ (2003). Reliability of smooth pursuit, fixation, and saccadic eye movements. Psychophysiology, 40, 620-628.
  • Ettinger U, Kumari V, Chitnis XA, Corr PJ, Sumich AL, Rabe-Hesketh S, Crawford TJ, Sharma T (2002). Relationship between brain structure and saccadic eye movements in healthy humans. Neuroscience Letters, 328(3), 225-228.
  • Ettinger U, Corr PJ (2001). The Frequency Accrual Speed Test (FAST): Psychometric intelligence and personality correlates. European Journal of Personality, 15(2), 143-152.
  • Ettinger U, Chitnis XA, Kumari V, Fannon DG, Sumich AL, O’Ceallaigh S, Doku V, Sharma T (2001). Magnetic resonance imaging of the thalamus in first-episode psychosis. American Journal of Psychiatry, 158(1), 116-118.

 

Übersichtsartikel

  • Ettinger U, Kumari V (2015). Effects of Sleep Deprivation on Inhibitory Biomarkers of Schizophrenia: Implications for Drug Development. Lancet Psychiatry, 2(11), 1028-1035.
  • Ettinger U, Mohr C, Gooding DC, Cohen AS, Rapp A, Haenschel C, Park S (2015). Cognition and Brain Function in Schizotypy: A Selective Review. Schizophrenia Bulletin, 41, S417-S426.
  • Cohen AS, Park S, Mohr C, Ettinger U, Chan R (2015). Schizotypy as an organizing framework for social and affective sciences. Schizophrenia Bulletin, 41, S427-S435.
  • Mohr C, Ettinger U (2014). An Overview of the Association between Schizotypy and Dopamine. Frontiers in Psychiatry, 5(184), 1-13.
  • Wright B, Peters E, Ettinger U, Kuipers E, Kumari V (2014). Understanding Noise Stress-Induced Cognitive Impairment and Its Implications for Schizophrenia. Noise & Health, 16(70), 166-176.
  • Ettinger U, Meyhöfer I, Steffens M, Wagner M, Koutsouleris N (2014). Genetics, Cognition and Neurobiology of Schizotypal Personality: A Review of the Overlap with Schizophrenia. Frontiers in Psychiatry. 5:18.
  • Koychev I, Barkus E, Ettinger U, Killcross S, Roiser J, Wilkinson L, Deakin JFW (2011) Evaluation of state and trait biomarkers in healthy volunteers for new drug treatments in schizophrenia. Journal of Psychopharmacology, 25, 1207-1225.
  • Haraldsson HM, Ettinger U, Sigurdsson E (2011). Developments in schizophrenia genetics: from linkage to microchips, deletions and duplications. Nordic Journal of Psychiatry, 65(2), 82-88.
  • Hutton SB, Ettinger U (2006). The antisaccade task as a research tool in psychopathology: A critical review. Psychophysiology, 43, 302-313.
  • Mitterschiffthaler MT, Ettinger U, Mehta MA, Mataix-Cols D, Williams SCR (2006). Applications of functional magnetic resonance imaging in psychiatry. Journal of Magnetic Resonance Imaging, 23, 851-861.
  • Ettinger U, Kumari V (2003). Pharmacological studies of smooth pursuit and antisaccade eye movements in schizophrenia: current status and directions for future research. Current Neuropharmacology, 1(4), 285-300.

 

Andere Publikationen

  • Ettinger U (in press). Gehirn und Geist. Kapitel in Kühnhardt L, Mayer T (Ed.), Bonner Enzyklopädie der Globalität.
  • Ettinger U, Klein C (in press). Eye Movements. Kapitel in Reuter M, Montag C (Ed.), Neuroeconomics, Berlin: Springer Verlag.
  • Mohr C, Ettinger U (2015). The role of dopamine in schizotypy. Chapter in Mason O, Claridge G (Ed.), Schizotypy: New Dimensions, London and New York: Routledge, pp. 33-47.
  • Migo E, Williams SCR, Crum W, Kempton M, Ettinger U (2011). The role of neuroimaging biomarkers in personalised medicine for neuro-degenerative and psychiatric disorders. Chapter 3 in Gordon E, Koslow SH (Ed.), Integrative Neuroscience and Personalized Medicine, Oxford University Press, pp. 141-163.
  • Kumari V, Ettinger U (2010). Latent inhibition in schizophrenia and schizotypy: a review of the empirical literature. Chapter 17 in Lubow R, Weiner I (Ed.), Latent Inhibition: Cognition, Neuroscience, and Applications to Schizophrenia, Cambridge University Press, pp. 419-447.
  • Klein C, Ettinger U (2008). A hundred years of eye movement research in psychiatry. Brain and Cognition, 68, 215-218.
  • Kumari V, Ettinger U (2005). Prepulse inhibition deficits in schizophrenia: Static or amenable to treatment? Chapter 6 in Lang MV (Ed.), Trends in Schizophrenia Research, Nova Science Publishers, pp. 95-117.
  • Ettinger U (2002). Review of the 11th World Congress of Psychophysiology. Journal of Advances in Schizophrenia and Brain Research, 4(4), 146-147.

 

 

Vorträge

  • Oculomotor Endophenotypes. European Summer School on Eye Movements, Athen, Griechenland, September 2016
  • "The Drugs Don't Work": Oculomotor Biomarkers in Psychopharmacology. European Summer School on Eye Movements, Athen, Griechenland, September 2016
  • The Dopamine Transporter: From Molecular Imaging and Pharmacology to Cognition and Clinical Symptoms. Eingeladener Vortrag, Institut für Psychologie, Universität Düsseldorf, Düsseldorf, Juli 2016
  • Die Schizotypie: Ein Phänotyp im Spektrum der Schizophrenie. Eingeladener Vortrag, Qualitätszirkel Bergisch Gladbach, Juni 2016
  • The Role of the Dopamine Transporter in Cognition. Eingeladener Vortrag, Psychologisches Institut, Deutsche Sporthochschule, Köln, Juni 2016
  • The Dopamine Transporter: From Molecular Imaging and Pharmacology to Cognition and Clinical Symptoms. Eingeladener Vortrag, Klinik und Poliklinik für Psychiatrie, Psychotherapie und Psychosomatik, Martin-Luther-Universität Halle-Wittenberg, Halle, Mai 2016
  • The Dopamine Transporter: From Molecular Imaging and Pharmacology to Cognition and Clinical Symptoms. Tagung experimentell arbeitender Psychologen (TeaP), Heidelberg, März 2016
  • Neuroenhancement. Eingeladener Vortrag, Institut für Wissenschaft und Ethik, Universität Bonn, Januar 2016
  • Neuroimaging, Cognitive and Pharmacological Studies of Schizotypal Personality. Eingeladener Vortrag, Department of Psychology, University of Edinburgh, UK, September 2015
  • "Found in Translation": Modellsysteme der Schizophrenie – Ketamin, Schlafentzug und Schizotypie. Eingeladener Vortrag, Universitäre Psychiatrische Kliniken Basel, Schweiz, Februar 2015
  • Neuroimaging, Cognitive and Pharmacological Studies of Schizotypal Personality: Evidence of a Continuum with Schizophrenia? Eingeladener Vortrag, Department of Psychology, City University, London, UK, Februar 2015
  • Schlafentzug induziert Defizite in der Präpulsinhibition und Psychose-ähnliche Symptome. Deutsche Gesellschaft für Schlafforschung und Schlafmedizin (DGSM), Köln, Dezember 2014
  • "The Drugs Don't Work" – Eye Movements as Biomarkers in Psychopharmacology. European Summer School on Eye Movements, Freiburg, September 2014
  • Are Endophenotypes the End of Phenotypes? European Summer School on Eye Movements, Freiburg, September 2014
  • Human Model Systems of Schizophrenia. British Association for Psychopharmacology, Cambridge, UK, Juli 2014
  • Neuroimaging, Cognitive and Pharmacological Studies of Schizotypal Personality: Evidence of a Continuum with Schizophrenia? Eingeladener Vortrag, Klinik für Psychiatrie und Psychotherapie, Universität Marburg, Marburg, Dezember 2013
  • Biological Approaches to Schizotypy: Evidence of a Continuum with Schizophrenia? Plenary Lecture, Lemanic Workshop on Schizotypy, Genf, Schweiz, Dezember 2013
  • Pharmacological Influences on Inhibitory Control. Eingeladener Vortrag, Forschungszentrum Jülich, November 2013
  • Die Rolle der Okulomotorik in der Kognitionsforschung. Eingeladener Vortrag, Centre for Economics and Neuroscience, Universität Bonn, November 2013
  • Oculomotor Endophenotypes. European Summer School on Eye Movements, Bonn, September 2013
  • Neuroimaging, Cognitive and Pharmacological Studies of Schizotypal Personality: Evidence of a Continuum with Schizophrenia? Eingeladener Vortrag, Department of Psychiatry, National University, Athen, Griechenland, März 2013
  • Neuroimaging, Cognitive and Pharmacological Studies of Schizotypal Personality: Evidence of a Continuum with Schizophrenia? Robert Sommer Award Symposium, Gießen, Februar 2013
  • Cognitive and Neural Effects of Acute Methylphenidate in Healthy Humans. DGPPN, Berlin, November 2012
  • Effects of Nicotine and Antipsychotics on Cognitive Control: The Role of Schizotypy. DGPPN, Berlin, November 2012
  • Neurocognitive Studies of Intra-subject Variability. 48. Kongress der Deutschen Gesellschaft für Psychologie, Bielefeld, September 2012
  • Effects of Risperidone, Amisulpride and Nicotine on Antisaccade Eye Movements and their Modulation by Schizotypy. 48. Kongress der Deutschen Gesellschaft für Psychologie, Bielefeld, September 2012
  • fMRI Ergebnisse zur Neurokognition schizophrener Erkrankungen. Abschiedssymposium zu Ehren von Herrn Prof. Dr. H.-J. Möller, LMU München, Juli 2012
  • Neural Mechanisms of Cognitive Enhancement. Eingeladener Vortrag, Bonner Imaging Seminar, Universität Bonn, Mai 2012
  • Neurocognitive Approaches to Schizotypal Personality. Eingeladener Vortrag, Klinik für Epileptologie, Universität Bonn, Mai 2012
  • Pharmacological Influences on Oculomotor Control in Healthy Humans. Vision Sciences Society, Naples, USA, Mai 2012
  • Neurocognitive Mechanisms of Inhibitory Control. TeaP, Mannheim, April 2012
  • DFG Emmy Noether-Programm: Erfahrungsbericht. Workshop "Forschen in Europa: Nationale und europäische Forschungsförderung", LMU München, März 2012
  • The Study of Oculomotor Control: Taking a Close Look at Cognition and Brain (Dys-)Function. Eingeladener Vortrag, Klinik für Psychiatrie, Universität Bonn, Februar 2012
  • Neurocognitive Approaches to Schizotypal Personality. Eingeladener Vortrag, Klinik für Psychiatrie und Psychotherapie, Erlangen, Februar 2012
  • Effects of Methylphenidate on Cognition and Brain Function. Eingeladener Vortrag, Institute of Psychiatry, London, UK, Januar 2012
  • Neurokognitive Untersuchungen der Schizotypie. Eingeladener Vortrag, Klinik für Psychiatrie, LMU München, Januar 2012
  • Neurokognitive Mechanismen der Inhibitionsfähigkeit. Ringvorlesung Kognitionswissenschaft, Institut für Psychologie, Humboldt-Universität zu Berlin, November 2011
  • Methylphenidate Effects on Neural Activity during Response Inhibition in Healthy Humans. AGNP Tagung, München, Oktober 2011
  • Neurokognitive Untersuchungen schizotyper Persönlichkeit. Symposium zu Ehren von Prof. Dr. Rolf Engel, LMU München, Oktober 2011
  • Die Rolle des Neurotizismus in der Assoziation zwischen Schizotypie und Kognition. DPPD Fachgruppentagung, Saarbrücken, September 2011
  • Genetic and Neuroimaging Studies of Antisaccades in the Schizophrenia Spectrum. European Conference on Eye Movements, Marseille, Frankreich, August 2011
  • Biological Approaches to the Study of Schizotypal Personality. Conference of the International Society for the Study of Individual Differences, London, UK, Juli 2011
  • Neurokognitive Untersuchungen der Schizotypie. Eingeladener Vortrag, Universitätsklinikum Ulm, Juli 2011
  • Einfluss von Methylphenidat auf die neuronalen Korrelate der Inhibitionsfähigkeit. Tagung Psychologie & Gehirn, Heidelberg, Juni 2011
  • Auswirkungen von Methylphenidat auf die Okulomotorik bei gesunden Probanden. Tagung Psychologie & Gehirn, Heidelberg, Juni 2011
  • Neurobiological Approaches to the Study of Schizotypal Personality. Eingeladener Vortrag, Klinik für Psychiatrie und Psychotherapie, Universität Magdeburg, Mai 2011
  • Neurocognitive Approaches to the Study of Schizotypal Personality. Eingeladener Vortrag, Department of Psychology, University of East London, UK, April 2011
  • Einsatz von Stimulanzien: Neurobiologische Effekte. EEG-Tage, München, Februar 2011
  • Methylphenidat: Auswirkungen auf Kognition und Gehirnfunktion. Eingeladener Vortrag, Klinik für Kinder- und Jugendpsychiatrie, Universität Freiburg, Januar 2011
  • Genetic Studies of Neurophysiological Phenotypes in Schizophrenia. DGPPN, Berlin, November 2010
  • Functional Magnetic Resonance Imaging of a Parametric Working Memory Task in Schizophrenia: Relationship with Performance and Effects of Antipsychotic Treatment. DGPPN, Berlin, November 2010
  • Genetic and neuroimaging studies of eye movements. Symposium on Clinical Neurophysiology of Vision and on Eye Movements, Ljubljana, Slowenien, September 2010
  • Behavioural and Molecular Genetic Studies of Cognitive and Oculomotor Phenotypes. Eingeladener Vortrag, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Juni 2010
  • Molecular and behavioural genetic studies of oculomotor, cognitive and neuroimaging phenotypes. Eingeladener Vortrag, Abteilung Allgemeine Psychologie, Justus-Liebig-Universität Giessen, Juni 2010
  • Okulomotorische Endophänotypen der Schizophrenie. Tagung Psychologie und Gehirn, Greifswald, Juni 2010
  • Endophänotypen der Schizophrenie: Okulomotorik und Neuroimaging. Eingeladener Vortrag, Psychiatrische Poliklinik der Universität Basel, Schweiz, März 2010
  • Neurobiologische Effekte von Methylphenidat bei Gesunden und Patienten, EEG-Tage, München, Februar 2010
  • Oculomotor (Endo-)Phenotypes and Biomarkers. Eingeladener Vortrag, Institut für Medizinische Psychologie, Ludwig-Maximilians-Universität, München, Januar 2010
  • Are endophenotypes the end of phenotypes? Cognitive Neuropsychiatry Conference, Bremen, November 2009
  • Effects of acute nicotine on brain function in healthy smokers and non-smokers: Estimation of inter-individual response heterogeneity. AGNP Tagung, München, Oktober 2009
  • Eye movements in schizophrenia: Recent evidence from genetics and neuroimaging. Plenary Lecture, British Ocular Motor Group Annual Meeting, Liverpool, UK, Januar 2009
  • The role of psychology in brain science. Eingeladener Vortrag, Wycombe Abbey School, High Wycombe, UK, Dezember 2008
  • Imaging and oculomotor endophenotypes of schizophrenia. Eingeladener Vortrag, Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, London, UK, Oktober 2008
  • Psychophysiologische und bildgebende Endophänotypen der Schizophrenie. Eingeladener Vortrag, Klinik für Psychiatrie und Psychotherapie der Universitätsmedizin Göttingen, Oktober 2008
  • Effects of nicotine on brain function during saccadic eye movements. XXVI CINP Congress, München, July 2008
  • Imaging and pharmacological studies of oculomotor inhibition. 16th European Congress of Psychiatry, Nizza, Frankreich, April 2008
  • Genetic and neuroimaging studies of antisaccade eye movements in schizophrenia. 16th European Congress of Psychiatry, Nizza, Frankreich, April 2008
  • Psychology careers. Eingeladener Vortrag, John Hampden Grammar School, High Wycombe, UK, März 2008
  • Genetic and neuroimaging studies of oculomotor endophenotypes in schizophrenia. Eingeladener Vortrag, Klinik für Psychiatrie und Psychotherapie, RWTH Aachen, Januar 2008
  • Genetic and neuroimaging studies of oculomotor endophenotypes in schizophrenia. Eingeladener Vortrag, Institut für Psychologie, Universität Würzburg, Würzburg, Januar 2008
  • Genetic and brain imaging studies of schizophrenia – the role of psychology. Eingeladener Vortrag, Eton College Psychological Society, Eton, UK, Oktober 2007
  • Genetic and Neuroimaging Studies of Oculomotor Endophenotypes. 1st European Conference on Schizophrenia Research, Düsseldorf, September 2007
  • Genetic and neuroimaging studies of eye movements in schizophrenia. Eingeladener Vortrag, Kneesworth House Hospital, Royston, UK, Mai 2007
  • Einfluss von Nikotin auf Hirnaktivierung während einer okulomotorischen Arbeitsgedächtnisaufgabe bei gesunden Männern. Tagung experimentell arbeitender Psychologen (TeaP), Trier, März 2007
  • Look away! Genetic and neuroimaging studies of antisaccade eye movements in schizophrenia. Eingeladener Vortrag, School of Psychology, Birkbeck College, London, UK, März 2007
  • Look away! Genetic and neuroimaging studies of antisaccade eye movements in schizophrenia. Eingeladener Vortrag, Department of Psychology, University of Wales, Bangor, UK, März 2007
  • Look away! Genetic and neuroimaging studies of antisaccade eye movements in schizophrenia. Eingeladener Vortrag, Neuroimaging Meeting, Institute of Psychiatry, London, Februar 2007
  • Careers for Psychology PhD's: Academia & Beyond. Panel discussant, Higher Education Academy Psychology Network. Southbank University, London, Dezember 2006
  • Relationship between prepulse inhibition and oculomotor control in schizophrenia. Cognitive Neuropsychiatry Congress, Bremen, Dezember 2006
  • Look Away! Genetic and neuroimaging studies of antisaccade eye movements. Eingeladener Vortrag, Institut für Psychologie, Ludwig-Maximilians-Universität, München, November 2006
  • Response inhibition and generation in the antisaccade task: an event-related fMRI study. Society for Psychophysiological Research, Vancouver, Kanada, Oktober 2006
  • Magnetic resonance imaging of the thalamus and adhesio interthalamica in twins with schizophrenia. Deutsche Gesellschaft für Biologische Psychiatrie, München, Oktober 2006
  • Oculomotor deficits as endophenotypes for schizophrenia. Eingeladener Vortrag, Psychiatrische Universitätsklinik, Bonn, März 2006
  • Antisakkadendefizite bei Schizophrenie. Tagung Experimentell Arbeitender Psychologen, Mainz, März 2006
  • Antisakkadendefizite bei Angehörigen und Zwillingen von Schizophrenen. Deutsche Gesellschaft für Psychiatrie, Psychotherapie, und Nervenheilkunde Congress, Berlin, November 2005
  • Taking a close look at schizophrenia: Genetic, pharmacological and neuroimaging studies of antisaccade eye movements. Eingeladener Vortrag, Department of Psychology, University of Wales, Swansea, UK, Oktober 2005
  • Taking a close look at schizophrenia: Genetic, pharmacological and neuroimaging studies of antisaccade eye movements. Eingeladener Vortrag, Department of Psychology, Thames Valley University, London, UK, März 2005
  • Taking a close look at schizophrenia: Eye movement tasks as tools in genetic, pharmacological and neuroimaging studies. Eingeladener Vortrag, Max-Planck-Institut für Hirnforschung, Frankfurt, Juni 2004
  • Antisaccades, schizotypy, and the role of neuroticism. 11th Biennial Meeting of the International Society for the Study of Individual Differences, Graz, Austria, Juli 2003
  • Eye movement endophenotypes in genetic and pharmacological studies of schizophrenia. Eingeladener Vortrag, Broadmoor Hospital, Crowthorne, UK, Juli 2003
  • Eye movements in schizophrenia: Current status and directions for future research. Eingeladener Vortrag, Institut für Psychologie, Humboldt-Universität zu Berlin, Berlin, Juli 2003
  • Eye movements in schizophrenia: Current status and directions for future research. Eingeladener Vortrag, Klinik für Neurologie II, Otto-von-Guericke-Universität Magdeburg, Magdeburg, Juli 2003
  • Eye movements in schizophrenia: Current status and directions for future research. Eingeladener Vortrag, Affective Neuroscience Group, Department of Psychology, Goldsmiths College, London, UK, Mai 2003
  • Eye movements as schizophrenia endophenotypes. Eingeladener Vortrag, Division of Psychiatry, Landspitali University Hospital, Reykjavik, Island, November 2002
  • Smooth pursuit and antisaccade eye movements in siblings discordant for schizophrenia. Eingeladener Vortrag, Departement de Psychiatrie Générale, Université de Lille II, Lille, Frankreich, Juni 2002
  • Smooth pursuit and antisaccade eye movements in siblings discordant for schizophrenia. Eingeladener Vortrag, Psychosis Interest Group, Institute of Psychiatry, London, UK, Mai 2002
  • Eye movements and the genetics of schizophrenia. Eingeladener Vortrag, Department of Clinical Psychology, Northwick Park Hospital, London, UK, März 2002
  • Neural correlates of saccadic eye movements in first-episode psychosis. 13th Annual Meeting of the British Ocular Motor Group, Imperial College, London, UK, Dezember 2001
  • First-episode psychosis, magnetic resonance imaging, and saccadic eye movements. Section of Cognitive Psychopharmacology Symposium, Institute of Psychiatry, London, UK, April 2001
  • Structural MRI correlates of saccade and antisaccade performance in healthy and schizophrenic subjects. The First Irish Workshop on Eye-Tracking, Trinity College Dublin, Irland, May 2000
  • Psychometric intelligence, personality, and neural correlates of Frequency Accrual Speed Test (FAST) performance. Eingeladener Vortrag, Mathematical Cognition Group, Department of Human Communication Science, University College London, UK, Februar 2000
  • Psychometric intelligence, personality, and neural correlates of Frequency Accrual Speed Test (FAST) performance. British Psychophysiology Society 27th Annual Meeting, Institute of Neurology, London, UK, Dezember 1999
  • Mental speed, intelligence, and personality. British Psychological Society Annual Conference, Student Group, Belfast, UK, April 1999
  • Klassische und IRT-Itemanalysen bei Leistungs- und Persönlichkeitstests. Seminar Aktuelle Probleme psychiatrischer Forschung aus psychologischer Sicht, Psychiatrische Klinik der LMU München, Dezember 1998
  • Mental speed, intelligence, and personality. BAAS Annual Festival of Science, Cardiff, UK, September 1998

 

 

Vorsitze und (Co-)Organisation von Symposien und Workshops

  • "European Summer School on Eye Movements". Athen, Griechenland, September 2016
  • "From Molecules to Mind". Tagung experimentell arbeitender Psychologen (TeaP), Heidelberg, März 2016
  • "Schizotypie – neue neurobiologische Befunde aus Genetik, Kognition und Bildgebung". DGPPN, Berlin, November 2014
  • "European Summer School on Eye Movements", Freiburg, September 2014
  • "Experimentelle und klinische Untersuchungen des Dopamin-Systems". AGNP, München, September 2013
  • "European Summer School on Eye Movements". Bonn, September 2013
  • "Nicotine as a cognitive enhancer". DGPPN, Berlin, November 2012
  • "Neuromodulation of Visual Perception". Vision Sciences Society, Naples, USA, May 2012
  • "Cognitive Control: Experimental Psychology and Cognitive Neuroscience". TeaP, Mannheim, April 2012
  • "Integrating Philosophy and Neuroscience in the Study of Consciousness: How to Make it Work". Centre for Advanced Studies, LMU München, Dezember 2011
  • "Interindividuelle Differenzen von Emotionalität: Neue Befunde aus Genetik und Experimentalpsychologie". DPPD Fachgruppentagung, Saarbrücken, September 2011
  • "Neuroscientific approaches to personality: from basic research to clinical implications". Conference of the International Society for the Study of Individual Differences, London, UK, Juli 2011
  • "Neuere Entwicklungen in der Pharmakopsychologie". Tagung Psychologie & Gehirn, Heidelberg, Juni 2011
  • "The intermediate phenotype strategy in schizophrenia and psychotic bipolar disorder”. DGPPN, Berlin, November 2010
  • "Treatment Effects on Cognition and Brain Function in Schizophrenia”. DGPPN, Berlin, November 2010
  • "Molecular Genetics and Neuroscience II”. Tagung Psychologie und Gehirn, Greifswald, Juni 2010
  • "Structural and functional imaging of the brain in twins with schizophrenia”. European Psychiatric Association, München, Februar 2010
  • "Neuropsychobiology of inhibitory deficits in schizophrenia: an update”. 16th European Congress of Psychiatry, Nizza, France, April 2008
  • "Psychopharmakologie und Experimentalpsychologie". Tagung experimentell arbeitender Psychologen (TeaP), Trier, März 2007
  • "Neural correlates of oculomotor control: basic and clinical research”. Society for Psychophysiological Research, Vancouver, Kanada, Oktober 2006
  • "Experimentalpsychologische Ansätze in der Schizophrenieforschung”. Tagung Experimentell Arbeitender Psychologen, Mainz, März 2006
  • "Augenbewegungen als Indikatoren für Störungen kortikaler Netzwerke bei psychiatrischen Störungen”. Deutsche Gesellschaft für Psychiatrie, Psychotherapie, und Nervenheilkunde Congress, Berlin, November 2005
  • "Symposium of the Section of Cognitive Psychopharmacology". Institute of Psychiatry, London, UK, April 2001

 

Artikelaktionen